Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 148

1.

Loss-of-Function Mutations in Human Regulator of G Protein Signaling RGS2 Differentially Regulate Pharmacological Reactivity of Resistance Vasculature.

Phan HTN, Jackson WF, Shaw VS, Watts SW, Neubig RR.

Mol Pharmacol. 2019 Dec;96(6):826-834. doi: 10.1124/mol.119.116822. Epub 2019 Oct 23.

PMID:
31645376
2.

An Interhelical Salt Bridge Controls Flexibility and Inhibitor Potency for Regulators of G-protein Signaling Proteins 4, 8, and 19.

Shaw VS, Mohammadi M, Quinn JA, Vashisth H, Neubig RR.

Mol Pharmacol. 2019 Dec;96(6):683-691. doi: 10.1124/mol.119.117176. Epub 2019 Sep 22.

PMID:
31543506
3.

Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay.

Benham V, Bullard B, Dexheimer TS, Bernard MP, Neubig RR, Liby KT, Bernard JJ.

Sci Rep. 2019 Jul 16;9(1):10278. doi: 10.1038/s41598-019-46531-y.

4.

Spermine in semen of male sea lamprey acts as a sex pheromone.

Scott AM, Zhang Z, Jia L, Li K, Zhang Q, Dexheimer T, Ellsworth E, Ren J, Chung-Davidson YW, Zu Y, Neubig RR, Li W.

PLoS Biol. 2019 Jul 9;17(7):e3000332. doi: 10.1371/journal.pbio.3000332. eCollection 2019 Jul.

5.

RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.

Lionarons DA, Hancock DC, Rana S, East P, Moore C, Murillo MM, Carvalho J, Spencer-Dene B, Herbert E, Stamp G, Damry D, Calado DP, Rosewell I, Fritsch R, Neubig RR, Molina-Arcas M, Downward J.

Cancer Cell. 2019 Jul 8;36(1):68-83.e9. doi: 10.1016/j.ccell.2019.05.015. Epub 2019 Jun 27.

6.

The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice.

Leal AS, Misek SA, Lisabeth EM, Neubig RR, Liby KT.

Sci Rep. 2019 May 8;9(1):7072. doi: 10.1038/s41598-019-43430-0.

7.

5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.

Kahl DJ, Hutchings KM, Lisabeth EM, Haak AJ, Leipprandt JR, Dexheimer T, Khanna D, Tsou PS, Campbell PL, Fox DA, Wen B, Sun D, Bailie M, Neubig RR, Larsen SD.

J Med Chem. 2019 May 9;62(9):4350-4369. doi: 10.1021/acs.jmedchem.8b01772. Epub 2019 Apr 18.

8.

A Two-Pulse Cellular Stimulation Test Elucidates Variability and Mechanisms in Signaling Pathways.

Sumit M, Jovic A, Neubig RR, Takayama S, Linderman JJ.

Biophys J. 2019 Mar 5;116(5):962-973. doi: 10.1016/j.bpj.2019.01.022. Epub 2019 Jan 30.

PMID:
30782397
9.

Mouse models of GNAO1-associated movement disorder: Allele- and sex-specific differences in phenotypes.

Feng H, Larrivee CL, Demireva EY, Xie H, Leipprandt JR, Neubig RR.

PLoS One. 2019 Jan 25;14(1):e0211066. doi: 10.1371/journal.pone.0211066. eCollection 2019.

10.

Interplay of cysteine exposure and global protein dynamics in small-molecule recognition by a regulator of G-protein signaling protein.

Mohammadi M, Mohammadiarani H, Shaw VS, Neubig RR, Vashisth H.

Proteins. 2019 Feb;87(2):146-156. doi: 10.1002/prot.25642. Epub 2018 Dec 26.

PMID:
30521141
11.

In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosis.

Tagalakis AD, Madaan S, Larsen SD, Neubig RR, Khaw PT, Rodrigues I, Goyal S, Lim KS, Yu-Wai-Man C.

J Nanobiotechnology. 2018 Nov 27;16(1):97. doi: 10.1186/s12951-018-0425-3.

12.

Interpreting Hydrogen-Deuterium Exchange Events in Proteins Using Atomistic Simulations: Case Studies on Regulators of G-Protein Signaling Proteins.

Mohammadiarani H, Shaw VS, Neubig RR, Vashisth H.

J Phys Chem B. 2018 Oct 11;122(40):9314-9323. doi: 10.1021/acs.jpcb.8b07494. Epub 2018 Oct 1.

13.

Role of hippocampal 5-HT1A receptors in the antidepressant-like phenotype of mice expressing RGS-insensitive Gαi2 protein.

Senese NB, Oginsky M, Neubig RR, Ferrario C, Jutkiewicz EM, Traynor JR.

Neuropharmacology. 2018 Oct;141:296-304. doi: 10.1016/j.neuropharm.2018.09.002. Epub 2018 Sep 4.

14.

A mechanistic review on GNAO1-associated movement disorder.

Feng H, Khalil S, Neubig RR, Sidiropoulos C.

Neurobiol Dis. 2018 Aug;116:131-141. doi: 10.1016/j.nbd.2018.05.005. Epub 2018 May 24. Review.

PMID:
29758257
15.

Differential Protein Dynamics of Regulators of G-Protein Signaling: Role in Specificity of Small-Molecule Inhibitors.

Shaw VS, Mohammadiarani H, Vashisth H, Neubig RR.

J Am Chem Soc. 2018 Mar 7;140(9):3454-3460. doi: 10.1021/jacs.7b13778. Epub 2018 Feb 26.

16.

Role of signalling molecules in behaviours mediated by the δ opioid receptor agonist SNC80.

Dripps IJ, Boyer BT, Neubig RR, Rice KC, Traynor JR, Jutkiewicz EM.

Br J Pharmacol. 2018 Mar;175(6):891-901. doi: 10.1111/bph.14131. Epub 2018 Feb 9.

17.

Human Missense Mutations in Regulator of G Protein Signaling 2 Affect the Protein Function Through Multiple Mechanisms.

Phan HTN, Sjögren B, Neubig RR.

Mol Pharmacol. 2017 Oct;92(4):451-458. doi: 10.1124/mol.117.109215. Epub 2017 Aug 7.

PMID:
28784619
18.

Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations.

Feng H, Sjögren B, Karaj B, Shaw V, Gezer A, Neubig RR.

Neurology. 2017 Aug 22;89(8):762-770. doi: 10.1212/WNL.0000000000004262. Epub 2017 Jul 26.

19.

Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis.

Yu-Wai-Man C, Spencer-Dene B, Lee RMH, Hutchings K, Lisabeth EM, Treisman R, Bailly M, Larsen SD, Neubig RR, Khaw PT.

Sci Rep. 2017 Mar 31;7(1):518. doi: 10.1038/s41598-017-00212-w.

20.

The DRY motif and the four corners of the cubic ternary complex model.

Rovati GE, Capra V, Shaw VS, Malik RU, Sivaramakrishnan S, Neubig RR.

Cell Signal. 2017 Jul;35:16-23. doi: 10.1016/j.cellsig.2017.03.020. Epub 2017 Mar 24. Review.

PMID:
28347873

Supplemental Content

Loading ...
Support Center